Nasdaq compliance removes near-term delisting risk but does not change INM's weak fundamental outlook, the stock still trades near the $1 threshold with minimal analyst support. Monitor upcoming quarterly results for any revenue or pipeline catalyst that could sustain the bid price above $1.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 10 $1.51entry
- T+1 · 5mo ago +4.64%α +2.94% · $1.58
- T+5 · 5mo ago −1.99%α −5.42% · $1.48
- T+20 · 4mo ago +9.93%α +6.31% · $1.66
- T+60 · 2mo ago −11.92%α −18.50% · $1.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a delisting notice received on March 27, 2026. The company demonstrated a closing bid price at or above $1.00 for 10 consecutive business days through June 2, 2026. This is a procedural compliance update, it removes an immediate delisting overhang but does not change the company's operational or financial trajectory.
Key Facts
- InMed received a Nasdaq deficiency notice on March 27, 2026 for non-compliance with the $1.00 bid price rule (Rule 5550(a)(2))
- Nasdaq confirmed compliance on June 3, 2026, based on 10 consecutive business days (May 19–June 2, 2026) with closing bid at or above $1.00
- The matter is now closed with no further action required by Nasdaq
- Company has a market cap of ~$4M and analyst consensus is 0% bullish (3 Hold, 4 Sell, 1 Strong Sell)
Financial Impact
No direct financial impact; removal of delisting risk removes a potential liquidity and capital-access overhang
Risk Factors
- Stock could fall back below $1.00, triggering a new deficiency process
- No revenue or operational catalyst announced, continued listing remains dependent on share price stability
- Low market cap and bearish analyst consensus suggest limited institutional support
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062993-26-003132 |
| Exhibit: exhibit99-1.htm | 0001062993-26-003132 |
| Document: 0001062993-26-003132-index-headers.html | 0001062993-26-003132 |
| Document: 0001062993-26-003132-index.html | 0001062993-26-003132 |
| Document: 0001062993-26-003132.txt | 0001062993-26-003132 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers